Viemed Healthcare (VMD) has kicked off 2026 with Q1 revenue of US$75.4 million and basic EPS of US$0.07. This compares with trailing twelve month revenue of US$286.6 million and EPS of US$0.39 that reflect 21.2% earnings growth over the last year. The company has seen quarterly revenue move from US$59.1 million and EPS of US$0.07 in Q1 2025 to US$75.4 million and EPS of US$0.07 in Q1 2026. This sets the scene for investors to weigh that earnings profile against a 5.2% net margin that keeps attention firmly on profitability quality in this latest update.

See our full analysis for Viemed Healthcare.

With the headline numbers on the table, the next step is to line them up against the key narratives around growth, risks, and profitability to see which stories hold up and which start to look stretched.

TTM earnings up 21.2% with steadier quarter-to-quarter EPS

• Over the last 12 months, Viemed Healthcare produced net income of US$14.9 million and basic EPS of US$0.39, compared with quarterly EPS that has moved in a relatively tight range from US$0.07 in Q1 2025 to US$0.15 in Q4 2025 and US$0.07 in Q1 2026.
• Bulls point to this 21.2% trailing earnings growth and argue it supports a bigger step up in profitability, yet the quarterly pattern shows a more gradual shift.
  • On the bullish side, the narrative talks about margins rising toward 9.1% over time. The latest trailing net margin sits at 5.2%, only slightly above the quarterly Q1 2026 net income of US$2.6 million on US$75.4 million of revenue.
  • That mix of strong 12 month earnings growth and relatively stable quarterly EPS around the US$0.07 to US$0.15 band gives you a way to test how confident you are in the idea of a sharp margin step up versus a slower grind.

Short term stability in EPS alongside 21.2% trailing earnings growth is exactly what bullish and bearish investors interpret very differently, so it is worth seeing how each side frames the next few years of patient growth and service mix before deciding which story fits your view 🐂 Viemed Healthcare Bull Case

5.2% margin and government reimbursement risk

• The latest trailing net profit margin of 5.2% is close to last year’s 5.3%, and Q1 2026 net income of US$2.6 million on US$75.4 million of revenue shows that profitability is currently being earned on relatively thin margins.
• Critics highlight that this level of margin leaves limited room if reimbursement or costs move against the company, and the bearish narrative focuses heavily on that point.
  • Bears flag heavy exposure to Medicare and Medicaid, so a cut in allowable rates could matter quickly when only about US$2.6 million of profit is being earned on more than US$75 million of quarterly revenue.
  • The cautious view also notes that newer service lines can carry lower gross margins. Together with potential competitive bidding pressure on respiratory equipment, this could make it harder to lift that 5.2% trailing net margin if costs rise faster than revenue.

For a business tied closely to government reimbursement, a 5.2% profit margin keeps attention on how much room there really is if policies tighten or if newer, lower margin services grow faster than the core vent business 🐻 Viemed Healthcare Bear Case

Valuation gap between 22x P/E and DCF fair value

• The stock trades on a trailing P/E of 22x at a share price of US$8.52, below both peers at 48.7x and the US Healthcare industry at 25.2x, while the stated DCF fair value in the data is US$28.20 and the analyst consensus price target is US$13.00.
• What is interesting is how this valuation setup gives both bullish and bearish narratives something to point to.
  • Supporters of the bullish view emphasize that a 22x P/E combined with a DCF fair value of US$28.20 and a consensus target of US$13.00 leaves a sizeable gap relative to the current US$8.52 share price, especially with earnings in the data set expected to grow faster than the broader US market.
  • Skeptical investors, on the other hand, connect the modest 5.2% trailing margin and reliance on government payers with that discount multiple and argue it reflects the execution risk of turning forecasted revenue growth into higher quality, durable profits.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Viemed Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between the bullish and bearish narratives, now is a good time to review the numbers yourself, weigh the trade offs, and decide where you stand by checking the 4 key rewards and 1 important warning sign.

See What Else Is Out There

Viemed Healthcare’s 5.2% net margin, reliance on government reimbursement, and modest quarterly EPS movement highlight how tight profitability currently is for this stock.

If that thin buffer makes you uneasy and you want stocks where pricing or costs feel less fragile, it is worth scanning 74 resilient stocks with low risk scores right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.